Regimen Improved Survival in Children With High-Risk Wilms Tumors

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video, Dr. Dix, discusses the results of two phase III trials that showed that in children with high-risk Wilms tumor, treatment with vincristine and dactinomycin plus the addition of doxorubicin improved outcomes.

In this video, Dr. Dix, of the British Columbia Children’s Hospital in Vancouver, discusses results of two phase III Children’s Oncology Group clinical trials that found that in children with high-risk Wilms tumor, treatment with vincristine and dactinomycin plus the addition of doxorubicin improved outcomes. The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. Read our conference report on this study.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content
Pembrolizumab/Lenvatinib Elicits Meaningful Responses in High-Grade Serous PROC

Pembrolizumab/Lenvatinib Elicits Meaningful Responses in High-Grade Serous PROC

Megan Hollasch
March 17th 2025
Article

A phase 2 trial found that pembrolizumab plus lenvatinib elicited an overall response rate of 37.5% that consisted entirely of partial responses in high-grade serous PROC.

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

The adverse effect profile of abemaciclib plus hormonal therapy was comparable with prior reports of CDK4/6 inhibitors.

Abemaciclib Plus Hormonal Therapy Shows Promising Efficacy in LGSOC/EEC

Roman Fabbricatore
March 17th 2025
Article

The adverse effect profile of abemaciclib plus hormonal therapy was comparable with prior reports of CDK4/6 inhibitors.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Niraparib/Bevacizumab Maintenance Sustains HRQOL in Advanced Ovarian Cancer

Niraparib/Bevacizumab Maintenance Sustains HRQOL in Advanced Ovarian Cancer

Caroline Seymour
March 16th 2025
Article

Results from the OVARIO trial found HRQOL maintained with niraparib/bevacizumab maintenance in patients with advanced ovarian cancer.

Puxitatug samrotecan was well tolerated in patients with advanced or metastatic endometrial cancer.

Puxitatug Samrotecan Exhibits Efficacy in Advanced/Metastatic EC

Jax DiEugenio
March 16th 2025
Article

Puxitatug samrotecan was well tolerated in patients with advanced or metastatic endometrial cancer.